| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Valantine Hannah serves as a Director at CDNA and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 3 buys and 20 sells. Those positions are worth an estimated $1.5M at current prices.
Historically, Valantine Hannah's trades have earned a middling insider score of 51/100 across 12 rated trades. Over a 12-month horizon, 44.4% of those trades were profitable, with an average 12-month return of -28.2%.
The biggest single holding is CDNA (~$911K) as Director. The recent filings there lean toward selling, a net 51,452 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2024 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 2,915 | $37.75 | $110,041.25 | -62.3% | -23.6% | -11.0% | |
| Jan 16, 2024 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 2,915 | $37.97 | $110,682.55 | -62.3% | -31.4% | -6.9% | |
| Dec 15, 2023 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 2,915 | $36.12 | $105,289.80 | -62.3% | -30.5% | -30.2% | |
| Nov 15, 2023 | BBIO Bridgebio Pharma, Inc. | Director | Sale+OE | 2,915 | $30.00 | $87,450.00 | -62.3% | +13.7% | -18.3% | |
| Dec 29, 2021 | BBIO Bridgebio Pharma, Inc. | Director | Buy | 1,764 | $14.23 | $25,101.72 | New | -23.5% | -46.7% | |
| Dec 28, 2021 | BBIO Bridgebio Pharma, Inc. | Director | Buy | 3,433 | $12.96 | $44,475.94 | New | -22.3% | -49.8% |